Ixekizumab

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Ixekizumab
   1. Pharmacist Assessment Report
   2. Ixekizumab: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Ixekizumab: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Ixekizumab, so there is currently no new predicted indication. The drug’s recorded uses are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	5
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
axial spondyloarthritis	licence in another country
juvenile arthritis	licence in another country
psoriasis	licence in another country
psoriatic arthritis	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
ankylosing spondylitis

Australia Market Information

Licence	Product	Dosage form	Status
11032P	Taltz	Injection 80 mg in 1 mL single dose pre-	Valid

Safety Considerations

Warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for these.

Drug Interactions (100 interactions recorded; the main ones in the data are below):

• Major: adalimumab. Combining two biologic immunomodulators warrants particular caution.
• Moderate: warfarin, dicoumarol, apixaban and rivaroxaban (anticoagulants); simvastatin; tacrolimus; theophylline, aminophylline, oxtriphylline and roflumilast; fentanyl and hydrocodone; lidocaine; nifedipine; and tetanus toxoid vaccine.
• Minor: zinc salts (sulfate, acetate, gluconate and chloride).

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---